Existing and emerging therapies for managing constipation and diarrhea

Adil Eddie Bharucha, Mira M. Wouters, Jan Tack

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Functional bowel disorders (i.e., constipation and diarrhea) are characterized by abdominal pain, bloating, distention, and/or bowel habit abnormalities in the absence of obvious anatomic or physiologic abnormalities on routine diagnostic tests. These symptoms are attributable to gastrointestinal sensorimotor dysfunctions resulting from peripheral and/or central mechanisms. Available drugs target the underlying bowel disturbance (i.e., constipation, diarrhea, or both), supplemented when necessary by management of pain. Osmotic and stimulant laxatives, secretagogues, and serotonin 5-HT4 receptor agonists are approved for treating constipation. Loperamide, anticholinergic agents, rifaximin, bile-acid binding agents, eluxadoline, and clonidine are used to treat diarrhea. Several exciting new compounds, some of which have been evaluated in humans, are currently under development.

Original languageEnglish (US)
Pages (from-to)158-166
Number of pages9
JournalCurrent Opinion in Pharmacology
Volume37
DOIs
StatePublished - Dec 1 2017

Fingerprint

Constipation
Diarrhea
rifaximin
Serotonin 5-HT4 Receptor Agonists
Loperamide
Laxatives
Cholinergic Antagonists
Clonidine
Pain Management
Bile Acids and Salts
Routine Diagnostic Tests
Abdominal Pain
Habits
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Existing and emerging therapies for managing constipation and diarrhea. / Bharucha, Adil Eddie; Wouters, Mira M.; Tack, Jan.

In: Current Opinion in Pharmacology, Vol. 37, 01.12.2017, p. 158-166.

Research output: Contribution to journalReview article

@article{2b2e9fddb41f4d87acc8db8d0c524d0c,
title = "Existing and emerging therapies for managing constipation and diarrhea",
abstract = "Functional bowel disorders (i.e., constipation and diarrhea) are characterized by abdominal pain, bloating, distention, and/or bowel habit abnormalities in the absence of obvious anatomic or physiologic abnormalities on routine diagnostic tests. These symptoms are attributable to gastrointestinal sensorimotor dysfunctions resulting from peripheral and/or central mechanisms. Available drugs target the underlying bowel disturbance (i.e., constipation, diarrhea, or both), supplemented when necessary by management of pain. Osmotic and stimulant laxatives, secretagogues, and serotonin 5-HT4 receptor agonists are approved for treating constipation. Loperamide, anticholinergic agents, rifaximin, bile-acid binding agents, eluxadoline, and clonidine are used to treat diarrhea. Several exciting new compounds, some of which have been evaluated in humans, are currently under development.",
author = "Bharucha, {Adil Eddie} and Wouters, {Mira M.} and Jan Tack",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.coph.2017.10.015",
language = "English (US)",
volume = "37",
pages = "158--166",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Existing and emerging therapies for managing constipation and diarrhea

AU - Bharucha, Adil Eddie

AU - Wouters, Mira M.

AU - Tack, Jan

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Functional bowel disorders (i.e., constipation and diarrhea) are characterized by abdominal pain, bloating, distention, and/or bowel habit abnormalities in the absence of obvious anatomic or physiologic abnormalities on routine diagnostic tests. These symptoms are attributable to gastrointestinal sensorimotor dysfunctions resulting from peripheral and/or central mechanisms. Available drugs target the underlying bowel disturbance (i.e., constipation, diarrhea, or both), supplemented when necessary by management of pain. Osmotic and stimulant laxatives, secretagogues, and serotonin 5-HT4 receptor agonists are approved for treating constipation. Loperamide, anticholinergic agents, rifaximin, bile-acid binding agents, eluxadoline, and clonidine are used to treat diarrhea. Several exciting new compounds, some of which have been evaluated in humans, are currently under development.

AB - Functional bowel disorders (i.e., constipation and diarrhea) are characterized by abdominal pain, bloating, distention, and/or bowel habit abnormalities in the absence of obvious anatomic or physiologic abnormalities on routine diagnostic tests. These symptoms are attributable to gastrointestinal sensorimotor dysfunctions resulting from peripheral and/or central mechanisms. Available drugs target the underlying bowel disturbance (i.e., constipation, diarrhea, or both), supplemented when necessary by management of pain. Osmotic and stimulant laxatives, secretagogues, and serotonin 5-HT4 receptor agonists are approved for treating constipation. Loperamide, anticholinergic agents, rifaximin, bile-acid binding agents, eluxadoline, and clonidine are used to treat diarrhea. Several exciting new compounds, some of which have been evaluated in humans, are currently under development.

UR - http://www.scopus.com/inward/record.url?scp=85034422540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034422540&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2017.10.015

DO - 10.1016/j.coph.2017.10.015

M3 - Review article

C2 - 29172123

AN - SCOPUS:85034422540

VL - 37

SP - 158

EP - 166

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -